CEACAM6 and lung cancer: In clinical studies, CEACAM6 was discovered to be highly expressed in non‐small cell lung cancer and overexpressed in over 80% of LUAD patients.[14] Among the entire onco‐embryonic antigen gene family, CEACAM6 is the most characteristic biomarker of numerous aggressive tumors.[15, 16] Therefore, CEACAM6 may serve as a potential biomarker and target for theranostics of LUAD.